NT PHARMA (01011) plans to issue convertible bonds with a total principal amount of HK $65 million.

NT Pharma (01011) announced that on February 9, 2026, the company entered into a subscription agreement with subscribers (Hangzhou Jingwei Life Science Technology Co., Ltd. and Mr. Huang Jianshan). According to this agreement, the subscribers have conditionally agreed to subscribe, and the company has conditionally agreed to issue HK$65 million principal amount of two-year unsecured 5% convertible bonds due in 2028. The total proceeds from the issuance of the bonds and the net proceeds are expected to be approximately HK$65 million and HK$64 million, respectively. The company intends to use the net proceeds for general working capital and repayment of loans. As of the date of this announcement, the company has issued a total of 674 million shares. Assuming (i) there are no other changes in the company's existing equity; (ii) the conditions precedent under the subscription agreement are met by the final deadline or earlier; (iii) all the conversion rights attached to the HK$65 million bonds are fully exercised by the subscribers at a conversion price of HK$0.64 per share, the subscribers will have equity in 101.6 million shares, representing approximately 15.06% of the company's issued share capital as of the date of this announcement, and approximately 13.09% of the enlarged issued share capital after the issuance and distribution of conversion shares in accordance with the subscription agreement.